Cargando…

Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. (2022);6(1):327-338.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032418/ https://www.ncbi.nlm.nih.gov/pubmed/36943316 http://dx.doi.org/10.1182/bloodadvances.2022008146

Ejemplares similares

van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
Publicado: (2023)

Correction to Mishara et al. (2022)
Publicado: (2022)

Correction to Port et al. (2022)
Publicado: (2023)

Crouch S, Painter D, Barrans SL, et al. Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network. Blood Adv. 2022;6(21):5716-5731.
Publicado: (2023)

Karihtala K, Leivonen S-K, Karjalainen-Lindsberg M-L, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022;6(6):1919-1931.
Publicado: (2023)

Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296-1308.
Publicado: (2022)

Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Publicado: (2023)

Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
Publicado: (2023)

Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. J. Clin. Med. 2020, 9, 2142
por: Mina, Roberto, et al.
Publicado: (2020)

Erratum to “Diagnostic Algorithm to Reflect Regressive Changes of Human Papilloma Virus in Tissue Biopsies” by Lhee MJ, et al. (Yonsei Med J 2014;55:331-338.)
Publicado: (2017)

Erratum to “E.C. Lerner, E.S. Srinivasan, G. Broadwater, et al. Factors Associated With New-Onset Seizures Following Stereotactic Radiosurgery for Newly Diagnosed Brain Metastases. Adv Radiat Oncol. 2022;7:101054.”
por: Lerner, Emily Claire, et al.
Publicado: (2023)

Lisi V, Blanchard È, Vladovsky M, et al. Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia. Blood Adv. 2022;6(17):5160-5164.
Publicado: (2023)

Nawas MT, Sanchez-Escamilla M, Devlin SM, et al. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2022;6(22):5898-5907.
Publicado: (2023)

Kudo K, Kubota Y, Toki T, et al. Childhood acute myeloid leukemia with 5q deletion and HNRNPH1-MLLT10 fusion: the first case report. Blood Adv. 2022;6(10):3162-3166.
Publicado: (2022)

Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.
Publicado: (2022)

Erratum to "The Effectiveness of Endoscopic Radiofrequency Denervation of Medial Branch for Treatment of Chronic Low Back Pain" by Jeong SY, et al. (J Korean Neurosurg Soc 56 : 338-343, 2014)
Publicado: (2014)

Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022;6(4):1243-1254.
Publicado: (2023)

Uy GL, Newell LF, Lin TL, et al. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022;6(17):4989-4993.
Publicado: (2023)

Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
Publicado: (2019)

Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
Publicado: (2019)

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022;6(3):828-847.
Publicado: (2023)

Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
Publicado: (2021)

Aiello S, Gastoldi S, Galbusera M, et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv. 2022;6(3):866-881.
Publicado: (2022)

Palma-Barqueros V, Bury L, Kunishima S, et al. Expanding the genetic spectrum of TUBB1-related thrombocytopenia. Blood Adv. 2021;5(24):5453–5467.
Publicado: (2023)

Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.
Publicado: (2019)

Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607.
Publicado: (2023)

Correction to Lancet Respir Med 2022; 10: 327–36
Publicado: (2022)

Qi S-N, Yang Y, Song Y-Q, et al. First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020;4(13):3141-3153.
Publicado: (2021)

Mulder DT, Mahé ER, Dowar M, et al. CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. Blood Adv. 2018;2(23):3506-3514.
Publicado: (2019)

Miles J, Bailey SL, Obenaus AM, et al. Storage temperature determines platelet GPVI levels and function in mice and humans. Blood Adv. 2021;5(19):3839-3849.
Publicado: (2022)

Greenwood M, Trahair T, Sutton R, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Adv. 2021;5(24):5574-5583.
Publicado: (2023)

Huynh A, Arnold DM, Michael JV, et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv. 2023;7(2):246-250.
Publicado: (2023)

Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
Publicado: (2023)

Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400-2408.
Publicado: (2019)

Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111.
Publicado: (2022)

Mazzara S, Travaini L, Botta F, et al. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL. Blood Adv. 2023;7(4):630-643.
Publicado: (2023)

Response to Belgard et al.
por: Skafidas, E, et al.
Publicado: (2014)

Bødker JS, Brøndum RF, Schmitz A, et al. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood Adv. 2018;2(18):2400-2411.
Publicado: (2019)

Weisdorf D, Cooley S, Wang T, et al. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Adv. 2020;4(4):740-754.
Publicado: (2022)

Hertz L, Flormann D, Birnbaumer L, et al. Evidence of in vivo exogen protein uptake by red blood cells: a putative therapeutic concept. Blood Adv. 2023;7(6):1033-1039.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ni9rmmdhi858iblne9dbbp6l92